AstraZeneca starts to make modest profit from Covid-19 vaccine

AstraZeneca starts to make modest profit from Covid-19 vaccine The Anglo-Swedish company's third-quarter results showed the vaccine contributed one cent to core earnings per share of $1.08, a rise of 14%. Total product sales jumped 49% to $9.74 billion, as its vaccine sales topped $1 billion. https://ift.tt/eA8V8J